Skip to main content

Reimbursement

As the trend of shifting the site of infusion services from the physician office to the hospital outpatient department continues, so does the conversation about the revenue differences in doing so. Clearly, there can be substantial differentials; however, it is interesting that the largest differences stem from payer contracts. Read More ›


Value-Based Concerns for Oncologists in the US

Value based concerns for Oncologist in the United States


The definition of value by patients with cancer does not necessarily coincide with other definitions by other stakeholders. According to one breast cancer advocate, when patients are asked to define “value” in the context of their cancer treatment, cost is not the first thing that comes to mind. Read More ›

Payment models that align reimbursement to support treatment planning and care coordination encourage oncology care providers to adhere to cancer treatment pathways, said Jennifer Malin, MD, PhD, Staff Vice President for Clinical Strategy, Anthem, Thousand Oaks, CA, at the 2015 American Society of Clinical Oncology annual meeting. Read More ›


According to a recent study, 63.6% of oncologists surveyed favor the establishment of an independent panel of health experts to decide which treatments Medicare will pay for based on a cost-benefit analysis (Gogineni K, et al. J Clin Oncol. 2015;33:846-853). Less than 50% of patients and members of the general public think this is a good idea. The United Kingdom’s National Institute for Health and Care Excellence (NICE) is one model for such a panel. Read More ›


Page 5 of 8